BPHA

BPHA is a potent and orally active MMP-2, MMP-9 and MMP-14 inhibitor with IC50s of 12 nM, 16 nM and 17 nM, respectively. BPHA does not inhibit MMP-1, -3, and -7 (the IC50s are 974, >1000, and 795 nM, respectively) . BPHA has antiangiogenic and antitumor effects[1].

Product Specifications

CAS Number

[193807-60-2]

Product Name Alternative

Flufenamic acid butyl ester; Butyl flufenamate,MC 903; Calcipotriene

UNSPSC

12352005

Hazard Statement

H228-H315-H319

Target

MMP

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bpha.html

Purity

99.88

Solubility

DMSO : 350 mg/mL (ultrasonic)

Smiles

O=S(C1=CC=C(C2=CC=CC=C2)C=C1)(N[C@H](CC3=CC=CC=C3)C(NO)=O)=O

Molecular Formula

C21H20N2O4S

Molecular Weight

396.46

Precautions

P210-P240-P241-P264-P280-P302+P352-P305+P351+P338-P362+P364-P370+P378

References & Citations

[1]R Maekawa, et al. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res. 1999 Mar 15;59 (6) :1231-5.